PARP INHIBITORS IN OVARIAN CANCER: TOXICITY PROFILE
Today, the role of the genetic factor in the etiology of ovarian cancer is unquestionable. Genetic disorders in low-differentiated serous adenocarcinoma of ovaries in about 50 per cent of cases occur in the form of a lack of homologous DNA reparation. About 2/3 of these cases are associated with mutations in BRCA genes. The use of PARP inhibitors is a promising direction in the treatment of BRCA-mutated ovarian cancer, and a number of studies have proven their advantage. But because they are used in supporting mode, one of the basic requirements for this group of drugs is the toxicity profile. The most common complications in taking PARP-inhibitors are nausea, fatigue, vomiting, anaemia, thrombocytopenia. Olaparib has the lowest toxicity range of all the PARP inhibitors known today in the treatment of ovarian cancer..
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2017 |
|---|---|
| Erschienen: |
2017 |
| Enthalten in: |
Zur Gesamtaufnahme - year:2017 |
|---|---|
| Enthalten in: |
Медицинский совет - (2017), 6, Seite 24-29 |
| Sprache: |
Russisch |
|---|
| Beteiligte Personen: |
S. V. KHOKHLOVA [VerfasserIn] |
|---|
| Links: |
doi.org [kostenfrei] |
|---|
| Themen: |
|---|
| doi: |
10.21518/2079-701X-2017-6-24-29 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
DOAJ023232862 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | DOAJ023232862 | ||
| 003 | DE-627 | ||
| 005 | 20230505014145.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 230226s2017 xx |||||o 00| ||rus c | ||
| 024 | 7 | |a 10.21518/2079-701X-2017-6-24-29 |2 doi | |
| 035 | |a (DE-627)DOAJ023232862 | ||
| 035 | |a (DE-599)DOAJ020c14eb56d64a7f8231240eff4491dd | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a rus | ||
| 100 | 0 | |a S. V. KHOKHLOVA |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a PARP INHIBITORS IN OVARIAN CANCER: TOXICITY PROFILE |
| 264 | 1 | |c 2017 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 520 | |a Today, the role of the genetic factor in the etiology of ovarian cancer is unquestionable. Genetic disorders in low-differentiated serous adenocarcinoma of ovaries in about 50 per cent of cases occur in the form of a lack of homologous DNA reparation. About 2/3 of these cases are associated with mutations in BRCA genes. The use of PARP inhibitors is a promising direction in the treatment of BRCA-mutated ovarian cancer, and a number of studies have proven their advantage. But because they are used in supporting mode, one of the basic requirements for this group of drugs is the toxicity profile. The most common complications in taking PARP-inhibitors are nausea, fatigue, vomiting, anaemia, thrombocytopenia. Olaparib has the lowest toxicity range of all the PARP inhibitors known today in the treatment of ovarian cancer. | ||
| 650 | 4 | |a ovarian cancer | |
| 650 | 4 | |a parp inhibitors | |
| 650 | 4 | |a toxicity | |
| 653 | 0 | |a Medicine | |
| 653 | 0 | |a R | |
| 700 | 0 | |a O. A. SHILKINA |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i In |t Медицинский совет |d Remedium Group LLC, 2019 |g (2017), 6, Seite 24-29 |w (DE-627)DOAJ000029483 |x 26585790 |7 nnns |
| 773 | 1 | 8 | |g year:2017 |g number:6 |g pages:24-29 |
| 856 | 4 | 0 | |u https://doi.org/10.21518/2079-701X-2017-6-24-29 |z kostenfrei |
| 856 | 4 | 0 | |u https://doaj.org/article/020c14eb56d64a7f8231240eff4491dd |z kostenfrei |
| 856 | 4 | 0 | |u https://www.med-sovet.pro/jour/article/view/1883 |z kostenfrei |
| 856 | 4 | 2 | |u https://doaj.org/toc/2079-701X |y Journal toc |z kostenfrei |
| 856 | 4 | 2 | |u https://doaj.org/toc/2658-5790 |y Journal toc |z kostenfrei |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_DOAJ | ||
| 951 | |a AR | ||
| 952 | |j 2017 |e 6 |h 24-29 | ||